WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Israel Gaza: Netanyahu vows to press ahead with Rafah offensiveWaitangi 2024: Watch government leaders speak at the Treaty GroundsOneFour: How drill music trailblazers have divided AustraliaDespair in Gaza as fighting intensifies, despite Israel promise to scale back'It's a deliberate strategy to erase us' – Whanganui iwi prepare for national huiTruck driver grabs schoolgirl in 'concerning' West Auckland incidentParliament set to resume for 2024EDITORIAL: Nissan rebuke shows preying on suppliers still exists in JapanWeather: Easter weekend chill calls for extra layersEDITORIAL: Future of sports in Japan key to JOC review of Sapporo debacle
2.4494s , 6498.0859375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gleam news portal